# Rhythm Pharmaceuticals, Inc. clinical trials: 29 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 29 trials with Rhythm Pharmaceuticals, Inc. as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Rhythm Pharmaceuticals, Inc.: 29 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/rhythm-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 29
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 29, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 5, 2025 | NCT07156578 | A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) | Rhythm Pharmaceuticals, Inc. | Phase 2 | Enrolling by invitation | Hypothalamic Obesity | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07156578) |
| January 13, 2025 | NCT06772597 | A Study of Setmelanotide in Patients With Prader-Willi Syndrome | Rhythm Pharmaceuticals, Inc. | Phase 2 | Active not recruiting | Prader-Willi Syndrome, Obesity, Hyperphagia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06772597) |
| January 7, 2025 | NCT06760546 | A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) | Rhythm Pharmaceuticals, Inc. | Phase 3 | Recruiting | Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve... | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06760546) |
| September 19, 2024 | NCT06596135 | Open-Label Extension Study of Setmelanotide | Rhythm Pharmaceuticals, Inc. | Phase 3 | Completed | Obesity Associated With Defects in Leptin-melanocortin Pathway | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06596135) |
| February 2, 2024 | NCT06239116 | A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment | Rhythm Pharmaceuticals, Inc. | Phase 1/2 | Active not recruiting | Hypothalamic Obesity, Prader-Willi Syndrome, PWS | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06239116) |
| September 21, 2023 | NCT06046443 | A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity | Rhythm Pharmaceuticals, Inc. | Phase 2 | Completed | Hypothalamic Obesity | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06046443) |
| March 20, 2023 | NCT05774756 | A Trial of Setmelanotide in Acquired Hypothalamic Obesity | Rhythm Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | Hypothalamic Obesity | 143 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05774756) |
| January 18, 2022 | NCT05194124 | Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway | Rhythm Pharmaceuticals, Inc. | Phase 3 | Completed | Bardet-Biedl Syndrome, POMC Deficiency | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05194124) |
| January 11, 2022 | NCT05183802 | An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS) | Rhythm Pharmaceuticals, Inc. | Not applicable | Approved for marketing | Bardet-Biedl Syndrome (BBS), Obesity | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05183802) |
| October 26, 2021 | NCT05093634 | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | Rhythm Pharmaceuticals, Inc. | Phase 3 | Completed | Obesity, Genetic Obesity | 296 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05093634) |
| September 16, 2021 | NCT05046132 | Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants | Rhythm Pharmaceuticals, Inc. | Phase 4 | Completed | Healthy | 77 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05046132) |
| July 19, 2021 | NCT04966741 | Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity | Rhythm Pharmaceuticals, Inc. | Phase 3 | Completed | Bardet-Biedl Syndrome, POMC Deficiency Obesity, PCSK1 Deficiency Obesity, LEPR Deficiency Obesity | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04966741) |
| July 15, 2021 | NCT04963231 | DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway | Rhythm Pharmaceuticals, Inc. | Phase 2 | Completed | Genetic Obesity | 164 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04963231) |
| January 26, 2021 | NCT04725240 | Open-Label Study of Setmelanotide in Hypothalamic Obesity | Rhythm Pharmaceuticals, Inc. | Phase 2 | Completed | Hypothalamic Obesity | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04725240) |
| April 16, 2020 | NCT04348175 | A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment | Rhythm Pharmaceuticals, Inc. | Phase 1 | Completed | Renal Insufficiency | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04348175) |
| November 19, 2018 | NCT03746522 | Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With... | Rhythm Pharmaceuticals, Inc. | Phase 3 | Completed | Bardet Biedl Syndrome (BBS), Alström Syndrome (AS) | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03746522) |
| August 29, 2018 | NCT03651765 | Long Term Extension Trial of Setmelanotide | Rhythm Pharmaceuticals, Inc. | Phase 2/3 | Completed | Obesity Associated With Defects in Leptin-melanocortin Pathway | 205 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03651765) |
| August 8, 2018 | NCT03621007 | An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Function Mutations in the POMC... | Rhythm Pharmaceuticals, Inc. | Observational | Completed | POMC Deficiency Obesity, PCSK1 Deficiency Obesity, LEPR Deficiency Obesity | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03621007) |
| March 27, 2018 | NCT03479437 | The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry | Rhythm Pharmaceuticals, Inc. | Observational | Completed | Genetic Forms of Extreme Obesity | 303 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03479437) |
| September 19, 2017 | NCT03287960 | Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity | Rhythm Pharmaceuticals, Inc. | Phase 3 | Completed | Leptin Receptor Deficiency Obesity | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03287960) |
| August 25, 2017 | NCT03262610 | Setmelanotide in a Single Patient With Partial Lipodystrophy | Rhythm Pharmaceuticals, Inc. | Phase 2 | Completed | Hypertriglyceridemia, Obesity | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03262610) |
| January 6, 2017 | NCT03013543 | Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity | Rhythm Pharmaceuticals, Inc. | Phase 2 | Completed | Genetic Obesity, Obesity, Obesity Due to Melanocortin 4 Receptor Deficiency | 213 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03013543) |
| September 12, 2016 | NCT02896192 | Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity | Rhythm Pharmaceuticals, Inc. | Phase 3 | Completed | Pro-opiomelanocortin (POMC) Deficiency Obesity | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02896192) |
| July 29, 2016 | NCT02849977 | Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers | Rhythm Pharmaceuticals, Inc. | Observational | Completed | Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene... | 5,966 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02849977) |
| May 1, 2015 | NCT02431442 | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic... | Rhythm Pharmaceuticals, Inc. | Phase 1 | Completed | Overweight, Obese | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02431442) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 3 |
| Phase 1/2 | 2 |
| Phase 2 | 9 |
| Phase 2/3 | 1 |
| Phase 3 | 9 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 23 |
| Active not recruiting | 3 |
| Recruiting | 1 |
| Enrolling by invitation | 1 |
| Approved for marketing | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Obesity | 18 |
| Sexual Infantilism | 7 |
| Hyperphagia | 4 |
| Bardet-Biedl Syndrome | 4 |
| Prader-Willi Syndrome | 3 |
| Overweight | 3 |
| Proopiomelanocortin Deficiency | 2 |
| Obesity, Morbid | 1 |
| Septo-Optic Dysplasia | 1 |
| Optic Nerve Hypoplasia | 1 |
| Renal Insufficiency | 1 |
| Pediatric Obesity | 1 |
| Alstrom Syndrome | 1 |
| Smith-Magenis Syndrome | 1 |
| Hypertriglyceridemia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Exporters in the United States](https://specstream.ai/data/businesses/exporters/united-states)
- [Boat and ship manufacturers in the United States](https://specstream.ai/data/businesses/boat-and-ship-manufacturers/united-states)
- [Trinidadian restaurants in the United States](https://specstream.ai/data/businesses/trinidadian-restaurants/united-states)
- [Pharmaceutical products wholesalers in the United States](https://specstream.ai/data/businesses/pharmaceutical-products-wholesalers/united-states)
- [Importers in the United States](https://specstream.ai/data/businesses/importers/united-states)
